Brief: Immunocore Announces Data With First Soluble Tcr Therapy For People Living With Hiv

Immunocore Holdings

22/02/2023 13:51

Feb 22 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE ANNOUNCES INITIAL PHASE 1 SAFETY AND
PHARMACODYNAMIC
ACTIVITY DATA WITH FIRST SOLUBLE TCR THERAPY FOR PEOPLE LIVING
WITH HIV
    * IMMUNOCORE HOLDINGS PLC - DATA FROM SINGLE ASCENDING DOSE
PART
OF PHASE 1 TRIAL SHOWS IMC-M113V IS WELL TOLERATED
    * IMMUNOCORE HOLDINGS PLC - EXPECTED MARKERS OF T CELL
ACTIVATION
OBSERVED IN HALF OF PARTICIPANTS AT 15-MCG DOSE
    * IMMUNOCORE HOLDINGS PLC - PLASMA VIRAL LOAD REMAINED
SUPPRESSED
THROUGHOUT DOSING AND FOLLOW-UP
    * IMMUNOCORE HOLDINGS PLC - MULTIPLE ASCENDING DOSE PART OF
TRIAL
IS ENROLLING PARTICIPANTS TO IDENTIFY SAFETY AND ANTI-VIRAL
ACTIVITY

Source text for Eikon:  ID:nGNX3Q8X2k 
Further company coverage:  IMCR.O 
 ((Reuters.Briefs@thomsonreuters.com;))